Haemonetics Corporation
HAE
$56.66
-$1.80-3.08%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.88% | 35.84% | 42.17% | 42.64% | 2.76% |
| Total Depreciation and Amortization | -0.48% | 6.56% | 14.56% | 22.88% | 25.30% |
| Total Amortization of Deferred Charges | -22.09% | -22.09% | -22.09% | -22.09% | -8.24% |
| Total Other Non-Cash Items | 106.86% | 144.14% | 32.40% | -102.08% | -76.28% |
| Change in Net Operating Assets | 118.14% | 85.25% | 24.32% | -34.77% | -62.54% |
| Cash from Operations | 162.16% | 240.27% | 67.51% | -0.01% | -34.48% |
| Capital Expenditure | -1.46% | 9.50% | -3.53% | -3.02% | 30.07% |
| Sale of Property, Plant, and Equipment | -84.55% | -85.45% | -85.36% | 1,184.70% | 542.27% |
| Cash Acquisitions | 100.00% | 100.00% | 99.55% | 38.12% | 38.12% |
| Divestitures | 2,786.07% | 2,786.07% | 2,786.07% | 2,786.07% | -- |
| Other Investing Activities | -162.07% | -109.95% | -55.70% | 12.50% | 1.93% |
| Cash from Investing | 61.19% | 85.87% | 87.52% | 49.78% | 41.04% |
| Total Debt Issued | -100.00% | -100.00% | -100.00% | 763.64% | 763.64% |
| Total Debt Repaid | 98.89% | 98.90% | 99.18% | -595.76% | -5,277.38% |
| Issuance of Common Stock | -4.68% | 0.05% | -3.07% | 15.51% | 14.20% |
| Repurchase of Common Stock | -169.76% | -171.40% | -1,527.15% | -3,897.33% | -1,348.48% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.90% | 99.77% | 99.80% | -12,002.39% | -13,418.77% |
| Cash from Financing | -216.08% | -175.15% | -161.03% | 185.18% | 96.66% |
| Foreign Exchange rate Adjustments | 213.53% | -101.07% | 286.07% | 78.49% | -27,881.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -66.48% | 94.48% | -187.77% | 221.10% | 522.56% |